Skip Nav Destination
Close Modal
1-20 of 896
Search Results for international reference prices
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Journal Article
International Reference Pricing in the Context of US Drug Policy
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 779–796.
Published: 01 December 2022
...Richard Frank; Rena M. Conti; Jonathan Gruber Abstract International reference prices (IRP), also called external reference prices, are widely used across developed nations. IRP uses the prices paid in other countries to either inform negotiations with the pharmaceutical industry or as a cap...
View articletitled, <span class="search-highlight">International</span> <span class="search-highlight">Reference</span> <span class="search-highlight">Pricing</span> in the Context of US Drug Policy
View
PDF
for article titled, <span class="search-highlight">International</span> <span class="search-highlight">Reference</span> <span class="search-highlight">Pricing</span> in the Context of US Drug Policy
Journal Article
The Rhetorical Transformations and Policy Failures of Prescription Drug Pricing Reform under the Trump Administration
Available to Purchase
J Health Polit Policy Law (2021) 46 (6): 1053–1068.
Published: 01 December 2021
..., the Trump administration failed to implement any of their more ambitious reform ideas. This article considers three of the Trump administration's signature policies—state-sponsored prescription drug importation, Medicare Part B international reference pricing, and reforms to the Medicare Part D rebate...
View articletitled, The Rhetorical Transformations and Policy Failures of Prescription Drug <span class="search-highlight">Pricing</span> Reform under the Trump Administration
View
PDF
for article titled, The Rhetorical Transformations and Policy Failures of Prescription Drug <span class="search-highlight">Pricing</span> Reform under the Trump Administration
Journal Article
Pharmaceutical Policy Reform in the Russian Federation
Available to Purchase
J Health Polit Policy Law (2014) 39 (3): 691–705.
Published: 01 June 2014
... in generic prices in the EU. Evidence from the Netherlands shows that prices decreased by up to 93 percent for high-volume products after the introduction of tendering (Kanavos, Seeley, and Vandoros 2009 ). Neither internal reference pricing at the molecule level nor price caps would bring the needed...
FIGURES
Journal Article
Prescription Drug Priorities under the Biden Administration
Available to Purchase
J Health Polit Policy Law (2021) 46 (4): 599–609.
Published: 01 August 2021
... of an independent review board to recommend reasonable prices for new specialty drugs lacking competition in the US market will also be an important measure to lower US drug prices, yet its proposed use of international reference pricing may be more difficult to implement than expected (Gavulic, Pelletier-Fleury...
Journal Article
Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 709–729.
Published: 01 December 2022
... and international reference pricing (Ferrario et al. 2020 ). An examination of income and wealth inequalities and other social determinants that shape unequal pharmacotherapy access reinforces that medication disparities are inextricable from broader racial inequities in the United States. For example...
FIGURES
Journal Article
Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 755–778.
Published: 01 December 2022
... ). In Europe, however, international reference pricing is part of a broader strategy, not the sole criterion—and for good reason. International comparison helps reduce price discrimination among European nations; it does not ensure reasonable prices, because prices still reflect the manufacturer's monopoly...
FIGURES
View articletitled, Assessing US Pharmaceutical Policy and <span class="search-highlight">Pricing</span> Reform Legislation in Light of European <span class="search-highlight">Price</span> and Cost Control Strategies
View
PDF
for article titled, Assessing US Pharmaceutical Policy and <span class="search-highlight">Pricing</span> Reform Legislation in Light of European <span class="search-highlight">Price</span> and Cost Control Strategies
Journal Article
Regional International Organizations and Health: A Framework for Analysis
Available to Purchase
J Health Polit Policy Law (2022) 47 (1): 63–92.
Published: 01 February 2022
... of member states when negotiating drug reference prices, and mapping the capacity of drug production in the region to eventually coordinate industrial capacity for the production of generic drugs (UNASUR 2012 ). (The problem with international reference prices, whether in Europe or South America...
FIGURES
Journal Article
Health Care Financing Reforms in Germany: The Case for Rethinking the Evolutionary Approach to Reforms
Available to Purchase
J Health Polit Policy Law (2008) 33 (5): 979–1005.
Published: 01 October 2008
...-
ing to health care financing reforms was passed; these are listed in table
1. The scope of the individual laws vary from comprehensive, as in the
case of the Healthcare Structure Act (1993) and the SHI Modernization
Act (2003), to specific, as reflected by the Reference Price Adjustment Act...
Journal Article
Generic Drug Names and Social Welfare
Available to Purchase
J Health Polit Policy Law (2013) 38 (3): 573–597.
Published: 01 June 2013
... . www.leem.org/article/chiffre-daffaires (accessed December 23, 2012). López-Casasnovas G. Puig-Junoy J. . 2000 . “Review of the Literature on Reference Pricing.” Health Policy 54 , no. 2 : 87 – 123 . Medicines and Healthcare Products Regulatory Agency (MHRA) . 2003 . “Changing...
Journal Article
A Cross-National Comparison of Orphan Drug Policies: Implications for the U.s. Orphan Drug Act
Available to Purchase
J Health Polit Policy Law (1998) 23 (2): 265–290.
Published: 01 April 1998
... corporations for worldwide distribu-
tion. What remains unclear are the international effects associated with
orphan drug policies—in particular, the effect of the U.S. Orphan Drug
Act outside the United States. The unregulated market determination of
orphan drug prices in the United States, combined...
Journal Article
Introduction
Available to Purchase
J Health Polit Policy Law (2011) 36 (4): 771–774.
Published: 01 August 2011
...Harold A. Pollack © 2011 by Duke University Press 2011 References Marmor T. Oberlander J. White J. . 2009 . The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality . Annals of Internal Medicine 150 ( 7 ): 485 – 489 . Social...
Journal Article
Prices, Volume, and the Perverse Effects of the Variations Crusade
Available to Purchase
J Health Polit Policy Law (2011) 36 (4): 775–790.
Published: 01 August 2011
... costs (Wayne and Armstrong 2009; Armstrong and
Wayne 2009b; Wayne and Epstein 2010).
Evidence from Other Perspectives
The relative importance of price and volume looks quite different if one
considers investigations of cost control from other perspectives.4 Most
obvious are the international...
Journal Article
Misleading Congress About Drug Development: Reply
Available to Purchase
J Health Polit Policy Law (2008) 33 (2): 319–324.
Published: 01 April 2008
... -111. Waltham, MA: PAREXEL International. Public Citizen. 2001 . Rx R&D Myths: The Case Against the Drug Industry's R&D Scare Card . July 23. www.citizen.org/documents/rdmyths.pdf . Scherer, F. M., 1993 . Pricing, Profits, and Technological Progress in the Pharmaceutical Industry...
Journal Article
Regulating Managed Care: Pulling the Tails to Wag the Dogs
Available to Purchase
J Health Polit Policy Law (1999) 24 (5): 1191–1200.
Published: 01 October 1999
...David M. Frankford Copyright © 1999 by Duke University Press 1999 References Breyer , S. G. 1982 . Regulation and Its Reform. Cambridge: Harvard University Press. Frankford , D. M. 1996 . Food Allergy and the Health Care Financing Administration: A Story of Rage. Widener...
Journal Article
Commercial Importation of Prescription Drugs in the United States: Short-Run Implications
Available to Purchase
J Health Polit Policy Law (2011) 36 (2): 295–316.
Published: 01 April 2011
... of Biopharmaceuticals: An International Comparison . Health Affairs 25 : 1353 – 1362 . ———. 2008 . International Prices and Availability of Pharmaceuticals in 2005 . Health Affairs 27 : 221 – 233 . Danzon P. Wang Y. R. Wang L. . 2005 . The Impact of Price Regulation on the Launch...
Journal Article
Has the Erosion of the Medical Marketplace Ended?
Available to Purchase
J Health Polit Policy Law (1988) 13 (2): 263–278.
Published: 01 April 1988
...
innovations. Whether expenditures and price indices will continue to increase at
historic rates will thus depend on whether consumers, acting either individually
or collectively, are willing to pay for the bulk of the innovations. Based on HMO
and international experience, there is reason to think...
Journal Article
Twenty Years of Using Economic Evaluations for Drug Reimbursement Decisions: What Has Been Achieved?
Available to Purchase
J Health Polit Policy Law (2013) 38 (6): 1081–1102.
Published: 01 December 2013
... on an international level. This happens in Australia, where in some instances the PBAC will recommend listing only if the manufacturer lowers the price. It is also beginning to happen in the United Kingdom, through the patient access schemes. Also, as a result of using economic evaluation, therapy is being delivered...
FIGURES
Journal Article
Misleading Congress About Drug Development
Available to Purchase
J Health Polit Policy Law (2007) 32 (5): 895–913.
Published: 01 October 2007
... rhetoric that all new drugs are thera-
peutically better than old ones, when five-sixths of them are not (National
Institute for Health Care Management Research and Education Founda-
tion 2002; Prescrire International 2004). Equally misleading is using the
label “new” to claim that if prices...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 621–628.
Published: 01 December 2022
..., and Sachs 2021 ; Padula 2019 ). The case for reform is compelling. The United States spends more on prescription drugs than any of our international peers, reflecting the absence of systemwide controls on prices. In 2018, drug prices in the United States were 256% of the prices in other Organization...
Journal Article
Targets and Systems of Health Care Cost Control
Available to Purchase
J Health Polit Policy Law (1999) 24 (4): 653–696.
Published: 01 August 1999
... on appropriateness of care is to impose a capacity
constraint, the technocratic pursuit of appropriateness normally refers to
less blunt measures, making appropriateness a separate theory.
3. Among other statements of the price/volume (or price/quantity) distinction, see Barer,
Lomas, and Sanmartin 1996.
660...
1
